A Study to Assess Adjuvant Immunotherapy With Nivolumab Plus Relatlimab Versus Nivolumab Alone After Complete Resection of Stage III-IV Melanoma
Clinical trial NCT05002569 · TERMINATED
Trial details
- NCT number
- NCT05002569
- Sponsor
- Bristol-Myers Squibb
- Status
- TERMINATED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2021-10-19
- Primary completion
- 2024-12-16
- Enrollment
- 1093
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.